Optimum Strategic Communications is pleased to support Versameb during World Continence Week, a company raising awareness of the high unmet medical need of patients suffering with Stress Urinary Incontinence (SUI) and continence related issues which impacts the lives of millions of patients worldwide.
Versameb’s Chief Executive Officer, Klaas Zuideveld to present on the Company’s proprietary VERSagile mRNA technology platform and lead therapeutic candidate, VMB-100, a potential treatment for Stress Urinary Incontinence. VMB-100 has first-and best-in-class potential and has generated promising pre-clinical data showing muscle tissue regeneration and function restoration of the urinary sphincter. Approximately 30% of adult women worldwide suffer from SUI. There is currently no drug treatment approved that restores function and has a long-term effect. VERSagile mRNA technology is well suited for the regeneration of muscle tissue and VMB-100 aims to make a difference in this hard-to-treat disease.
Listen to the full webinar presentation here, at 2:30pm BST / 3:30pm CET today! (24th June 2022)
For more information and resources on SUI, please see Versameb’s SUI fact sheet.